Vaxcyte PCVX

$ 88.81 3.32%

Quarterly report 2024-Q3
added 11-05-2024

Vaxcyte Balance Sheet 2011-2024 | PCVX

Annual Balance Sheet Vaxcyte

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-368 M	-817 M	-53.1 M	-	-58.8 M	-65.6 M	-	-	-	-	-	-	-
Long Term Debt	22.1 M	12 M	11.5 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	7.11 M	5.91 M	5.28 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	161 M	122 M	-	-	-	-	-	-	-
Total Current Liabilities	145 M	40.5 M	28.7 M	46.9 M	-	-	-	-	-	-	-	-	-
Total Liabilities	167 M	52.6 M	40.3 M	47 M	172 M	129 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-924 M	-522 M	-299 M	-199 M	-109 M	-59.1 M	-	-	-	-	-	-	-
Total Assets	1.41 B	1.01 B	324 M	393 M	65.7 M	70.8 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	397 M	835 M	69.9 M	386 M	59 M	66.1 M	-	-	-	-	-	-	-
Book Value	1.24 B	954 M	284 M	346 M	-106 M	-57.7 M	-	-	-	-	-	-	-
Total Shareholders Equity	1.24 B	954 M	284 M	346 M	-106 M	-57.7 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Vaxcyte

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	18.3 M	18.3 M	20.2 M	22.1 M	7.78 M	9.22 M	10.6 M	12 M	13.4 M	14.6 M	15.8 M	11.5 M	553 K	225 K	295 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	142 M	101 M	107 M	167 M	93.3 M	69.4 M	63.4 M	52.6 M	52.8 M	45.1 M	43.2 M	40.3 M	48.1 M	41 M	55.4 M	47 M	47 M	47 M	47 M	11.8 M	11.8 M	11.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.25 B	-1.15 B	-1.02 B	-924 M	-744 M	-651 M	-583 M	-522 M	-444 M	-386 M	-338 M	-299 M	-270 M	-243 M	-220 M	-199 M	-199 M	-199 M	-199 M	-109 M	-109 M	-109 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	3.56 B	2.09 B	2.09 B	1.41 B	1.5 B	1.5 B	1.01 B	1.01 B	412 M	412 M	403 M	324 M	354 M	358 M	382 M	393 M	393 M	393 M	393 M	65.7 M	65.7 M	65.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	1.05 B	519 M	612 M	397 M	546 M	532 M	381 M	835 M	279 M	239 M	203 M	69 M	113 M	152 M	199 M	386 M	386 M	386 M	386 M	59 M	59 M	59 M	-	66.1 M	-	-	-	36.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	3.42 B	1.99 B	1.98 B	1.24 B	1.4 B	1.43 B	945 M	954 M	359 M	366 M	360 M	284 M	306 M	317 M	327 M	346 M	346 M	346 M	346 M	53.9 M	53.9 M	53.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	3.42 B	1.99 B	1.98 B	1.24 B	1.4 B	1.43 B	945 M	954 M	359 M	366 M	360 M	284 M	306 M	317 M	327 M	346 M	346 M	346 M	346 M	-106 M	-106 M	-106 M	-71.1 M	-57.7 M	-	-	-	-29.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency